BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.
Highlight from this Publication:
“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
BÜHLMANN fCAL®ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771.
Highlight from this Publication
“This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA]testing in primary care…..to be used as part of the pathway for management of patients with suspected IBS.”
BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.
Highlights from this Publication:
“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up toa cost avoidance of approximately up to €2.13 million.”
BUHLMANN Diagnostics Corp
105 Route 101A, Suite 1
Amherst, NH 03031
USA
(844) 300-9799
(603) 732-0675
info@buhlmannlabs.com
